Gian Maria Annovi

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 十一月 8, 2023
Patient, FDA, Research, Gian Maria Annovi, Standard of care, Kinetics, AD, PD, Patent, III, II, Human, Neurodegenerative disease, ADCS, Axonal transport, News, Conference, CNS, Inflammation, Data, PHL, ThinkEquity, Mouse, AAIC, American City Business Journals, Neurology, University of Washington School of Medicine, University, Brain, Safety, Movement, European, Death, Communication, Cognition, DSMB, Pharmaceutical industry, Vaccine, Cryptocurrency, Palladium

With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.

Key Points: 
  • With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
  • Financial Results (for the quarter ending September 30, 2023)
    Cash and cash equivalents were $6.4 million.
  • Maria Maccecchini, Ph.D, Annovis founder, president, and CEO, has been named a 2023 Woman of Influence by the Philadelphia Business Journal.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study

Retrieved on: 
星期四, 十月 12, 2023
NYSE, Safety, Update, DSMB, FDA, Gian Maria Annovi, Clutch (eggs), AD, PD, Patient, Cognition, Pharmaceutical industry

The Company has received the results of the pre-planned interim analysis conducted by an independent data analytics provider.

Key Points: 
  • The Company has received the results of the pre-planned interim analysis conducted by an independent data analytics provider.
  • The interim analysis was based on 107 patients at 6 weeks from all cohorts collectively and showed that the AD trial should continue as planned with the same trial size to maintain the statistical power for both co-primary endpoints.
  • A separate safety interim analysis is in process and we expect that interim analysis to be released in two weeks.
  • Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: “Although we remain blinded to the data, results from this interim analysis supports our original statistical powering for enrolling 320 patients into the Phase 2/3 Alzheimer’s study.

Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 八月 15, 2023
Mental Health, Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Xchange, Cognition, Axonal transport, Patent, Human, University, Gian Maria Annovi, PD, Senior, AE, DSMB, Bio, Neurodegenerative disease, Trial of the century, Brain, Inflammation, CNS, University of Washington School of Medicine, Thought, Movement, II, Research and development, Development, AAIC, TDP43, Patient, Data, European, ADCS, Mouse, Poster, AD, FDA, Therapy, Death, III, Memory, NYSE, News, Conference, Safety, Kinetics, Pharmaceutical industry, Tutoring, Cryptocurrency, Palladium, Buntanetap

Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced second quarter financial results for the period ended June 30, 2023, and reviewed recent accomplishments.

Key Points: 
  • Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced second quarter financial results for the period ended June 30, 2023, and reviewed recent accomplishments.
  • On June 3, Annovis announced it had reached full enrollment in the trial in a record nine months.
  • The planned enrollment has been achieved and based on this DSMB endorsement, Annovis expects topline results by the end of 2023.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

Annovis Bio Announces the Filing of a Groundbreaking Patent

Retrieved on: 
星期二, 六月 27, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Amyloid-related imaging abnormalities, Patent, Gian Maria Annovi, PD, Bleeding, AE, DSMB, Half-life, Bio, Cerebral edema, Movement, Șaeș, Thought, ARIA, TDP43, Data, Ecosystem, AD, Death, III, Memory, NYSE, Pharmaceutical industry

The patent is groundbreaking because ANVS402 offers significant advantages over the previous, less structured form, including better stability, higher purity, and longer half-life, improving buntanetap’s effectiveness.

Key Points: 
  • The patent is groundbreaking because ANVS402 offers significant advantages over the previous, less structured form, including better stability, higher purity, and longer half-life, improving buntanetap’s effectiveness.
  • The composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug.
  • Approval of this patent will come with protection of ANVS402 and all its uses for a 20-year patent term.
  • “Annovis is extremely excited about the potential of ANVS402 and its future iterations in the treatment of neurodegenerative diseases,” said Michael Hoffman, chairman of Annovis.

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 11, 2023
Teva Pharmaceuticals, Patent, Metal, Human, Gian Maria Annovi, PD, Alzheimer's disease, Environmental Toxicology and Pharmacology, United States Patent and Trademark Office, Clinical trial, Toxicology, ATM, Down syndrome, International Conference on Afghanistan, London (2006), Patient, Procházka, Process chemistry, Mouse, Research, AD, FDA, News, NYSE, Conference, Chemical process, Pharmaceutical industry, EU, Pharmacology

BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.

Key Points: 
  • BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.
  • At a recent R&D webcast on April 20, 2023, the Company:
    Reviewed its ongoing clinical programs in AD and PD.
  • Explained the results from the pre-planned blinded interim analysis of the ongoing Phase 3 study for early PD, announced on March 31, 2023.
  • Financial Results (for the quarter ending March 31, 2023)
    Cash and cash equivalents were $16.8 million.

Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans

Retrieved on: 
星期四, 四月 27, 2023
Overload, Heart, Patent, Metal, Gian Maria Annovi, United States Patent and Trademark Office, Cancer, Brain, IP, DSM-IV codes, Homeostasis, Messenger, Lung, Protein, Superoxide dismutase, Iron, Aconitase, Kidney, Liver, APP, NYSE, TSE, Pharmaceutical industry, Dietary supplement, Vaccine

U.S. Patent 11,596,621 B2 is titled, “Prevention or Treatment of Disease States Due to Metal Dis-homeostasis Via Administration of Posiphen [buntanetap] to Healthy or Sick Humans” and was issued on March 7, 2023.

Key Points: 
  • U.S. Patent 11,596,621 B2 is titled, “Prevention or Treatment of Disease States Due to Metal Dis-homeostasis Via Administration of Posiphen [buntanetap] to Healthy or Sick Humans” and was issued on March 7, 2023.
  • The patent is expected to confer protection for use of buntanetap and its related analogue molecules for the prevention and treatment of various neurodegenerative diseases associated with metal dis-homeostasis out to early 2040.
  • The ‘621 patent covers the use of buntanetap for maintaining or restoring heavy metal homeostasis as a method of prevention in healthy humans or as a method of treatment in sick humans.
  • Annovis Bio has patents that cover a wide range of chronic neurodegenerative as well as acute neurodegenerative diseases.

ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS

Retrieved on: 
星期四, 四月 13, 2023
FDA, Gian Maria Annovi, Parkinson's disease, Patient, NYSE, Alzheimer's disease, Disease, Pharmaceutical industry, Webcast

BERWYN, Pa., April 13, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will hold a live R&D webcast to review its clinical development programs in Alzheimer's disease and Parkinson's disease.

Key Points: 
  • Webcast to be held on Thursday, April 20th at 4pm EDT.
  • BERWYN, Pa., April 13, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will hold a live R&D webcast to review its clinical development programs in Alzheimer's disease and Parkinson's disease.
  • As part of the presentation, the Company will discuss why it believes buntanetap is uniquely positioned to address both symptomatic as well as disease modification in early and advanced-stage Alzheimer's and Parkinson's patients.
  • Following the presentation, the Company will hold a Question-and-Answer session.

Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

Retrieved on: 
星期三, 二月 1, 2023
Axonal transport, Patent, Huntington's disease, Brain, Medicine, DSM-IV codes, Human, ALS, PD, Protein, Neurotoxicity, Traumatic brain injury, Gian Maria Annovi, NYSE, Attention deficit hyperactivity disorder predominantly inattentive, ADHD, Schizophrenia, Inflammation, Bipolar disorder, Alzheimer's disease, Health, Spectrum, Stroke, Mental, CTE, AD, Chronic traumatic encephalopathy, Neurotransmission, Parkinson's disease, Prion, Communication, FTD, Frontotemporal dementia, Pharmaceutical industry, Dietary supplement, Vaccine, Lancet, Amyloid beta

In certain embodiments, the invention covers methods and pharmaceutical compositions of a large group of buntanetap analogs for preventing, treating, inhibiting, reducing, slowing, or delaying mental illnesses in humans.

Key Points: 
  • In certain embodiments, the invention covers methods and pharmaceutical compositions of a large group of buntanetap analogs for preventing, treating, inhibiting, reducing, slowing, or delaying mental illnesses in humans.
  • In certain embodiments, the mental illness is autism, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, or schizophrenia.
  • These neurotoxic proteins cause impairment in axonal transmission and inflammation, similar to what is seen in neurodegenerative diseases.
  • The Company has been issued patents covering a wide range of neurodegenerative diseases, and this patent, if granted, would represent a significant expansion of Annovis' intellectual property portfolio.

Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

Retrieved on: 
星期五, 一月 6, 2023
Parkinson's disease, Gian Maria Annovi, Toxicology, Chemical process, Laboratory, Pilot plant, Disease, Alzheimer's disease, Forest Products Laboratory, Research, NYSE, Teva Pharmaceuticals, Regulatory Toxicology and Pharmacology, FDA, Cephalon, Process, Neurodegeneration, Pharmaceutical industry, Pharmacology

BERWYN, Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.

Key Points: 
  • BERWYN, Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.
  • Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis commented, "The expertise of Dr. Michael Christie and David Prohaska will significantly strengthen our ability to conduct successful clinical trials and navigate the regulatory process.
  • Michael Christie, Ph.D., brings to Annovis over 40 years of experience in the pharmaceutical industry.
  • Mr. Prohaska joins Annovis from Aravive Biologics where he served as the Director of Preclinical Development and Clinical Operations Support.

Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Retrieved on: 
星期四, 九月 29, 2022
Risk, Inflammation, Memory, Human, Twitter, NYSE, Brain, AD, Neurodegeneration, Parkinson's disease, LinkedIn, Company, Cognition, Forward-looking statement, U.S. Securities and Exchange Commission, Patient, Annual report, Ladenburg, Security (finance), Conference, Pharmacokinetics, Ladenburg Thalmann, PD, Axonal transport, Gian Maria Annovi, Alzheimer's disease, Toxicity, Pharmaceutical industry

BERWYN, Pa., Sept. 29, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, in New York City.

Key Points: 
  • BERWYN, Pa., Sept. 29, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, in New York City.
  • Investors interested in arranging a one-on-one meeting at the conference should contact their Ladenburg Thalmann representative.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .
  • Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.